Kilian Eyerich

Hugstetter Str. 55
Freiburg, BW 79106, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 239 publications

Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.

Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.

Journal: The Journal of dermatological treatment

Published: June 01, 2026

Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD Study.

Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD Study.

Journal: Dermatology and therapy

Published: April 27, 2026

Non-communicable inflammatory skin diseases comprise clinically meaningful distinct endotypes as identified by non-hypothesized integration of phenotypic and transcriptome data.

Non-communicable inflammatory skin diseases comprise clinically meaningful distinct endotypes as identified by non-hypothesized integration of phenotypic and transcriptome data.

Journal: The Journal of allergy and clinical immunology

Published: April 16, 2026

New diagnostic possibilities in hand eczema

New diagnostic possibilities in hand eczema

Journal: Dermatologie (Heidelberg, Germany)

Published: April 10, 2026

From legacy subsets to auditable descriptors: implementing the 2025 T-cell nomenclature guidelines for inflammatory skin diseases.

From legacy subsets to auditable descriptors: implementing the 2025 T-cell nomenclature guidelines for inflammatory skin diseases.

Journal: The British journal of dermatology

Published: April 01, 2026

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis.

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis.

Journal: The Journal of dermatological treatment

Published: March 12, 2026

Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region.

Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region.

Journal: Dermatology and therapy

Published: February 23, 2026

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.

Journal: Dermatology and therapy

Published: February 13, 2026

Inhibition of Salt-Inducible Kinases 2 and 3 reduces inflammatory signature in Psoriasis.

Inhibition of Salt-Inducible Kinases 2 and 3 reduces inflammatory signature in Psoriasis.

Journal: The Journal of investigative dermatology

Published: January 14, 2026

European consensus recommendations for nummular eczema: A modified Delphi study.

European consensus recommendations for nummular eczema: A modified Delphi study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 12, 2026

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany.

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany.

Journal: International journal of cancer

Published: December 18, 2025

TRPA1 as a Key Regulator of Keratinocyte Homeostasis and Inflammation in Human Skin.

TRPA1 as a Key Regulator of Keratinocyte Homeostasis and Inflammation in Human Skin.

Journal: Cells

Published: December 11, 2025

Showing 1-12 of 239

Last Updated: 09/26/2026